is launching a Phase 3 clinical trial of its proposed drug for the treatment of mild cystic fibrosis.
The drug denufosol tetrasodium is an inhalation product.
The test will include a 24-week efficacy period and a 24-week safety extension period. Some 350 patients with mild cystic fibrosis will be involved in the study. Patients will inhale the drug three times a day.